EN DE
Watch Abivax SA for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Abivax SA (ABVX) fair value: what the stock is really worth

As of Nov 20, 2026: fair value (intrinsic value) of Abivax SA stock €27.92, price €63.00, that is 55.7% below the price, quality 26 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently applies, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare FR · ISIN FR0012333284

AS Abivax SA logo Thin data Nov 21, 2026

Abivax SA

ABVX · PA

Far too expensive (fair value 56% below the price), weak company and falling price: meets none of the 3 rules.

Follow free in the weekly email
Low debt 
Mixed Growth (revenue 3y +563.2 %/yr in EUR) 
Fair value €27.92 · Strongly overvalued 
Quality 26/100 
Falling price (downtrend) 
Negative free cash flow 
Trails peers (0/7) 
Narrow moat 9/100 · thin data
Thin data 
Estimate

Main risks:

🚩Price drop: Short seller report triggering sharp share drop🚩Short seller report on undisclosed drug toxicity risks🚩Rivals like AbbVie could erode market share
Watch Abivax SA for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€135.00 €4.56 Fair Value €27.92 Sep 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 21, 2026.

How to read this chart

60‑month range €4.56 – €135.00 · fair‑value band €20.94 – €34.90 · the €63.00 price screens above the €27.92 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 21, 2026.

Follow Abivax in your weekly email

Every Wednesday you see whether Abivax is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

ABIVAX, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.

Show moreShow less

Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.

Stock analysis

Abivax SA (ABVX) currently trades at €63.00, while our estimate is €27.92, 56% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently applies to this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: €20.94 (bear) to €34.90 (bull), the price of €63.00 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 26/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Abivax SA reported revenue of €0 in FY2025 versus €37.0K in FY2021. Reported net income was −€336M in FY2025.

Key figures

Market cap €5.5B Mid · EPS (TTM) €-5.21 · Return on equity −252% · Return on assets (EBIT) −61.6% (5-year average) · Operating margin −6,270% · Revenue (TTM) €4.7M · Revenue growth (quarter YoY) −6.8% · Free cash flow −€162M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (low confidence).

What moves the price

The share trades about 53% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −4% fair-value upside, at −56%, ABVX screens richer than that median.

Fair Value

Bear €20.94 Fair Value €27.92 Bull €34.90
Price €63.00 · Downside -55.7%
Estimate. None of our valuation models currently applies to this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 26/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 41
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 97
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 5
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 34/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+133.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+563.2%
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+57.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−2,344.7% (2018) → −1,718.2% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

ABVX screens overvalued: fair value 56% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Note from the team AI-generated · Nov 22, 2026
AI conclusion: Business quality rests on a narrow moat from its lead drug development, yet the main weakness lies in thin public data and pre-revenue negative cash flows of an early-stage biotech.
Main risk: Established players such as AbbVie with Rinvoq and Skyrizi or Johnson & Johnson with Stelara could take customers in the ulcerative colitis and Crohn’s market and force lower prices or margins for obefazimod.
Bull case: The company could differentiate obefazimod through its novel mechanism and secure partnerships or approvals that allow it to capture significant share despite competition.
Bear case: If larger rivals maintain dominance with their established products, Abivax might struggle to gain meaningful market penetration for its lead candidate.
A short seller report claims Abivax’s lead drug obefazimod shows toxic properties and photocarcinogenic risks not previously disclosed, triggering a sharp share drop. The company calls the allegations factually inaccurate and misleading while reaffirming its phase 3 data and plans to file an NDA by year end. Our models currently see the stock as overvalued. Will independent review confirm the safety profile or validate the new concerns?
Join the discussion →

Compare Abivax SA with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 856 stocks

Beats the industry median on 0/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 26 · Bottom 25%
Fair Value upside −55.7% · Bottom 25%
Profitability
Return on assets −57.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −6.8% · Below median
Balance sheet
Debt / equity 0.12× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 12.12× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 5
FUTURE (revenue growth)0 · sector 31
PAST (return on equity)0 · sector 0
HEALTH (low debt)94 · sector 96
DIVIDEND (yield)0 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $920.69 $1,275.02 +38% vs ABVX
Vertex Pharmaceuticals Incorporated VRTX $515.02 $566.52 +10% vs ABVX
Samsung Biologics Co 207940 ₩1,355,000 ₩1,490,500 +10% vs ABVX
argenx SE ARGX $925.70 $908.40 −2% vs ABVX
CSL Limited CSL A$197.29 A$188.80 −4% vs ABVX
BeOne Medicines AG 6160 HK$230.80 HK$152.92 −34% vs ABVX
Moderna, Inc MRNA $195.00 $122.98 −37% vs ABVX
Revolution Medicines, Inc RVMD $161.20 $83.14 −48% vs ABVX
Celltrion, Inc 068270 ₩213,000 ₩74,574 −65% vs ABVX
Royalty Pharma plc RPRX $68.45 $19.01 −72% vs ABVX

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Abivax SA: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Abivax SA Fair Value". https://www.fairvalue-calculator.com/stock/ABVX

Frequently asked questions

Is Abivax SA (ABVX) overvalued or undervalued?
As of Nov 21, 2026, our estimate of fair value is €27.92 versus a price of €63.00, about 56% lower (overvalued).
What is the fair value of ABVX?
Our estimate for Abivax SA is €27.92 (as of Nov 21, 2026), built from audited fundamentals. The current price: €63.00.
What is the quality score of ABVX?
Abivax SA has a Quality Score of 26/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Abivax SA (ABVX)?
We do not set a price target; the yardstick is our estimate of €27.92 (as of Nov 21, 2026). Cautious scenario €20.94, optimistic scenario €34.90. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently applies, not an analyst target.
What is the Abivax SA stock forecast for 2026?
Our estimate puts fair value at €27.92, about 56% lower versus a price of €63.00 (overvalued). Cautious scenario €20.94, optimistic scenario €34.90. The calculation is refreshed regularly with new filings.
What is the revenue of Abivax SA (ABVX)?
Abivax SA reported trailing-twelve-month revenue of about €4.7M (latest available figure, as of Nov 21, 2026).
What is the intrinsic value of Abivax SA (ABVX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Abivax SA it is €27.92 per share (as of Nov 21, 2026), against a price of €63.00.
Is Abivax SA stock overvalued or undervalued in 2026?
As of Nov 21, 2026, ABVX trades above its calculated fair value: price €63.00, fair value €27.92, a gap of about −56% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ABVX?
No. The price is what the market pays today (€63.00); the fair value is what the company's own numbers justify (€27.92). For Abivax SA the two are €35.08 per share apart. That gap is exactly why we show both numbers side by side.
How much is Abivax SA worth?
The market values Abivax SA at about €5.5B (market capitalisation, as of Nov 21, 2026). Per share that is €63.00; our models calculate a fair value of €27.92 per share.
What do the bullish and bearish scenarios say about ABVX?
Our models span a range for Abivax SA: cautious scenario €20.94, base €27.92, optimistic €34.90 per share (as of Nov 21, 2026, price €63.00). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Abivax SA (ABVX)?
Balance-sheet figures for Abivax SA (as of Nov 21, 2026): return on equity −252.4%, debt of 0.12 per unit of equity. They feed the Quality Score of 26/100, which measures business quality independently of the share price.
How far is ABVX from its 52-week high?
Abivax SA trades at €63.00, about 53% below its 52-week high of €135.00 and at the low of €63.00 (as of Nov 20, 2026). Distance from the high says nothing about value: that is what the fair value of €27.92 is for.
Which stocks are comparable to Abivax SA?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Abivax SA stock attractive at the current price?
The data as of Nov 21, 2026: price €63.00, calculated fair value €27.92 (−56%), Quality Score 26/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 10.1% above its aggregate fair value. Abivax SA itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Abivax SA (ABVX)?
The closing price on Nov 20, 2026 was €63.00. Our estimate is €27.92, about 56% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Abivax SA right now?
The price sits above even our optimistic bull case (€34.90). The favourable scenario is already priced in. Weak quality (26/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Abivax SA

How large is the market capitalisation of Abivax SA (ABVX)?
The market capitalisation of Abivax SA is €5.5B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Abivax SA (ABVX)?
Earnings per share at Abivax SA are €-5.21. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Abivax SA (ABVX)?
The return on equity (ROE) of Abivax SA is −252% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Abivax SA (ABVX)?
On an EBIT basis the return on assets of Abivax SA is −61.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Abivax SA (ABVX)?
The operating margin of Abivax SA is −6,270% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Abivax SA (ABVX)?
Revenue at Abivax SA is down 6.8% in the last quarter versus the same quarter a year earlier. How much revenue grew in the last quarter versus the same quarter a year earlier (YoY). The 3-year average next to it puts the single quarter in context.
How much free cash flow does Abivax SA (ABVX) generate?
The free cash flow of Abivax SA is −€162M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Abivax SA (ABVX) hold?
Abivax SA holds more cash than debt, €485M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Abivax SA in the live analysis

One click puts Abivax SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.